聚腺苷二磷酸核糖聚合酶在酒精性脂肪肝中的研究进展

摘要
图/表
参考文献(29)
相关文章 (5)

全文: PDF (457 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要酒精性脂肪肝（AFLD）是长期饮酒导致的肝脏疾病，长期的酒精摄入导致肝脏脂肪合成代谢增加和脂解作用减少，肝脏脂肪沉积增加，进而发生脂肪性肝炎、肝纤维化和肝硬化，其相关的病理机制尚未明确。聚腺苷二磷酸核糖聚合酶（PARP）是细胞内重要的DNA修复酶，主要参与细胞的基因转录、DNA修复、基因组的稳定和细胞的凋亡、坏死。PARP是细胞内烟酰胺腺嘌呤二核苷酸（NAD+）的消耗酶，PARP的活性改变对细胞内NAD+水平的调控发挥重要作用。长期的酒精摄入导致PARP蛋白活化，在AFLD的发生、发展中发挥重要作用。PARP蛋白的基因缺失或活性抑制，对改善长期饮酒导致的肝脏脂肪沉积、炎性反应、氧化应激和肝细胞的凋亡、坏死发挥重要作用，本文对PARP蛋白在AFLD中的研究进展进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄时顺刘洋张冰李欣包志伟王志刚▲

关键词 ：酒精性脂肪肝, 聚腺苷二磷酸核糖聚合酶, 烟酰胺腺嘌呤二核苷酸, 肝脂肪沉积

Abstract：Alcoholic fatty liver disease (AFLD) caused by chronic drinking which is one of liver disease. Chronic alcohol consumption increased hepatic fat anabolism and decreased lipolysis which caused hepatic fat accumulation. Moreover, chronic alcohol exposure induced steatohepatitis, hepatic fibrosis and cirrhosis. But the pathological mechanism is not yet clear. Poly (ADP-ribose) polymerase (PARP) is a intracellular DNA repairase which participated in intracellular gene transcription, DNA repair, genome stability and cell apoptosis and necrosis. PARP is a consumer of intracellular nicotinamide adenine dinucleotide (NAD+). The activation of PARP regulated the intracellular NAD+ level. Chronic alcohol consumption induced PARP activity which play an important role in the development of alcohol fatty liver disease. The inhibition of PARP or gene deletion of PARP in mice attenuated hepatic fat accumulation, inflammatory, oxidative stress and hepatic apotosis and necrosis by chronic alcohol exposure. This review focus on the advanced research of PARP in alcoholic fatty liver disease.

Key words： Alcoholic fatty liver disease Poly (ADP-ribose) polymerase Nicotinamide adenine dinucleotide Hepatic fatty accumulation

基金资助:国家自然科学基金资助项目（81370523）；
哈尔滨医科大学研究生创新基金项目（YJSCX2015-59HYD）。

通讯作者: ▲通讯作者

引用本文:

黄时顺刘洋张冰李欣包志伟王志刚▲. 聚腺苷二磷酸核糖聚合酶在酒精性脂肪肝中的研究进展[J]. 中国医药导报, 2017, 14(22): 51-54.
HUANG Shishun LIU Yang ZHANG Bing LI Xin BAO Zhiwei WANG Zhigang▲. Advanced in research of poly (ADP-ribose) polymerase in alcoholic fatty liver disease. 中国医药导报, 2017, 14(22): 51-54.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I22/51

[1] Kirpich IA，Miller ME，Cave MC，et al. Alcoholic liver disease: update on the role of dietary fat [J]. Biomolecules，2016， 6（1）：1.
[2] Saberi B，Dadabhai AS，Jang YY，et al. Current management of alcoholic hepatitis and future therapies [J]. J Clin Transl Hepatol，2016，4（2）： p.113-p.122.
[3] Livero FA，Acco A. Molecular basis of alcoholic fatty liver disease：from incidence to treatment [J]. Hepatol Res，2016， 46（1）：111-123.
[4] You M，Jogasuria A，Taylor C，et al. Sirtuin 1 signaling and alcoholic fatty liver disease [J]. Hepatobiliary Surg Nutr，2015，4（2）：88-100.
[5] Magdaleno F，Blajszczak CC，Nieto N. Key events participating in the pathogenesis of alcoholic liver disease [J]. Biomolecules，2017，7（1）. pii： E9.
[6] Ceni E，Mello T，Galli A. Pathogenesis of alcoholic liver disease：role of oxidative metabolism [J]. World J Gastroenterol，2014，20（47）：17756-17772.
[7] An L，Wang X，Cederbaum AI. Cytokines in alcoholic liver disease [J]. Arch Toxicol，2012，86（9）：1337-1348.
[8] Miller AM，Horiguchi N，Jeong WI，et al. Molecular mechanisms of alcoholic liver disease： innate immunity and cytokines [J]. Alcohol Clin Exp Res，2011，35（5）：787-793.
[9] Han J，Li E，Chen L，et al. The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1 [J]. Nature，2015，524（7564）：243-246.
[10] Kema VH，Mojerla NR，Khan I，et al. Effect of alcohol on adipose tissue： a review on ethanol mediated adipose tissue injury [J]. Adipocyte，2015，4（4）：225-231.
[11] 李园园，周俊英.脂素-1在酒精性脂肪肝发病机制中的作用[J].中华肝脏病杂志，2016，24（3）：237-240.
[12] Yamamoto H，Takada T，Yamanashi Y，et al. VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body [J]. Sci Rep，2017，7（1）：633.
[13] Pechlaner R，Tsimikas S，Yin X，et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-Ⅲ [J]. J Am Coll Cardiol，2017，69（7）：789-800.
[14] Dunning KR，Russell DL，Robker RL. Lipids and oocyte developmental competence：the role of fatty acids and β-oxidation [J]. Reproduction，2014，148（1）：R15-R27.
[15] Gaudet D，Drouin-Chartier JP，Couture P. Lipid metabolism and emerging targets for lipid-lowering therapy [J]. Can J Cardiol，2017，33（7）：872-882.
[16] Herceg Z，Wang ZQ. Functions of poly（ADP-ribose） polymerase （PARP） in DNA repair，genomic integrity and cell death [J]. Mutat Res，2001，477（1-2）：97-110.
[17] Sousa FG，Matuo R，Soares DG，et al. PARPs and the DNA damage response [J]. Carcinogenesis，2012，33（8）：1433-1440.
[18] Devalaraja-Narashimha K1，Padanilam BJ. PARP1 deficiency exacerbates diet-induced obesity in mice [J]. J Endocrino，2010，205（3）：243-252.
[19] Kraus WL，Hottiger MO. PARP-1 and gene regulation： progress and puzzles [J]. Mol Aspects Med. 2013，34（6）：109-123.
[20] Surjana D，Halliday GM，Damian DL. Role of nicotinamide in DNA damage，mutagenesis，and DNA repair [J]. J Nucleic Acids，2010，2010：1-13.
[21] Gariani K，Ryu D，Menzies KJ，et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease [J]. J Hepatol，2017，66（1）：132-141.
[22] Rappou E，Jukarainen S，Rinnankoski-Tuikka R，et al. Weight loss is associated with increased NAD（+）/SIRT1 expression but reduced PARP activity in white adipose tissue [J]. J Clin Endocrinol Metab，2016，101（3）：1263-1273.
[23] Mukhopadhyay P，Horváth B，Rajesh M，et al. PARP inhibition protects against alcoholic and nonalcoholic steatohepatitis [J]. J Hepatol，2017，66（3）：589-600.
[24] Huang K，Du M，Tan X，et al. PARP1-mediated PPARalpha poly（ADP-ribosyl）ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease [J]. J Hepatol，2017，66（5）：962-977.
[25] Wan J，Benkdane M，Teixeira-Clerc F，et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis： a protective mechanism against alcoholic and nonalcoholic fatty liver disease [J]. Hepatology，2014，59（1）：130-142.
[26] Kim KH，Kum YS，Park YY，et al. The protective effect of bee venom against ethanol-induced hepatic injury via regulation of the mitochondria-related apoptotic pathway [J]. Basic Clin Pharmacol Toxicol，2010，107（1）：619-624.
[27] Xu T，Zheng L，Xu L，et al. Protective effects of dioscin against alcohol-induced liver injury [J]. Arch Toxicol，2014， 88（3）：739-753.
[28] Londhe JS，Devasagayam TP，Foo LY，et al. Geraniin and amariin，ellagitannins from Phyllanthus amarus，protect liver cells against ethanol induced cytotoxicity [J]. Fitoterapia，2012，83（8）：1562-1568.
[29] Zhang Y，Wang C，Tian Y，et al. Inhibition of Poly（ADP-Ribose） Polymerase-1 protects chronic alcoholic liver injury [J]. Am J Pathol，2016，186（12）：3117-3130.